Damien N. Dombrowski

Representative Matters

After a five-day jury trial and over four years of litigation on behalf of client Vectura against defendant GlaxoSmithKline (GSK), Damien's team obtained an $89.7 million verdict of infringement, willful infringement, and non-obviousness of a Vectura patent on inhalation formulation technology, which the District Court increased to $107 million, and the jury further awarded an ongoing royalty on U.S. sales of GSK's infringing Breo Ellipta, Anoro Ellipta, and Incruse Ellipta inhaler products. The Federal Circuit affirmed. Among many other contributions to the litigation, Damien cross-examined GSK's main infringement and invalidity expert at trial and was the lead brief writer throughout the case and on appeal.

Representative Clients

• Advaxis
• Astellas
• Bausch & Lomb
• Canon
• Gilead
• LEO Pharma
• Merck
• Sanofi
• Vectura

Education

• J.D. Fordham University 2008
• B.S. Neurobiology University of Washington 2003
• B.S. Biochemistry University of Washington 2003
• • Minors in math and chemistry

Bar Admissions

• New York

Court Admissions

• U.S. Court of Appeals for the Federal Circuit
• U.S. District Court for the Southern District of New York
• U.S. District Court for the Eastern District of New York